Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
venetoclax + obinutuzumab
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (venetoclax), Intravenous (obinutuzumab)
01
Overview
**Venetoclax + obinutuzumab** is a fixed-duration, chemotherapy-free combination regimen approved for the first-line treatment of adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)[1][4][5][7]. **Venetoclax** is an orally bioavailable, selective small molecule inhibitor of B-cell lymphoma 2 (BCL-2), an anti-apoptotic protein overexpressed in CLL and other malignancies[2][4]. By inhibiting BCL-2, venetoclax promotes apoptosis of malignant B-cells. **Obinutuzumab** is a glycoengineered type II monoclonal antibody targeting the CD20 antigen on B-lymphocytes, enhancing antibody-dependent cellular cytotoxicity (ADCC), direct cell death, and immune-mediated killing of B-cells[4][6]. The combination produces higher response rates and longer progression-free survival than standard chemoimmunotherapy, with a favorable safety profile and fixed treatment duration (12 cycles)[1][4][7].
- Brand names
- Venclexta (venetoclax)Venclyxto (venetoclax)Gazyva (obinutuzumab)Gazyvaro (obinutuzumab)
- Other names
- venetoclax and obinutuzumab
02
Targets
BCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)
Beyond the preview
Go deeper on venetoclax + obinutuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on venetoclax + obinutuzumab.